{
    "id": 441,
    "fullName": "CTNNB1 wild-type",
    "impact": "none",
    "proteinEffect": "no effect",
    "geneVariantDescriptions": [
        {
            "description": "Wild-type CTNNB1 indicates that no mutation has been detected within the CTNNB1 gene.",
            "references": [
                {
                    "id": 275,
                    "pubMedId": null,
                    "title": "External Reference Not Available (N/A)",
                    "url": "https://ckb.jax.org/about/glossaryOfTerms"
                }
            ]
        }
    ],
    "type": "non-specific",
    "gene": {
        "id": 1499,
        "geneSymbol": "CTNNB1",
        "terms": [
            "CTNNB1",
            "armadillo",
            "CTNNB",
            "EVR7",
            "MRD19",
            "NEDSDV"
        ]
    },
    "variant": "wild-type",
    "createDate": "05/02/2014",
    "updateDate": "08/24/2017",
    "referenceTranscriptCoordinates": null,
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 7164,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Vantictumab (OMP-18R5) inhibited tumor growth in patient-derived xenograft models of colon cancer with wild-type CTNNB1 (beta-catenin) and APC (PMID: 22753465).",
            "molecularProfile": {
                "id": 24535,
                "profileName": "APC wild-type CTNNB1 wild-type"
            },
            "therapy": {
                "id": 4397,
                "therapyName": "Vantictumab",
                "synonyms": null
            },
            "indication": {
                "id": 219,
                "name": "colon cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 6127,
                    "pubMedId": 22753465,
                    "title": "Wnt pathway inhibition via the targeting of Frizzled receptors results in decreased growth and tumorigenicity of human tumors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22753465"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 525,
            "profileName": "CTNNB1 wild-type",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 24535,
            "profileName": "APC wild-type CTNNB1 wild-type",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        
    ]
}